162 related articles for article (PubMed ID: 20414345)
1. Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas.
Porrata LF; Inwards DJ; Micallef IN; Johnston PB; Ansell SM; Hogan WJ; Markovic SN
Clin Dev Immunol; 2010; 2010():914945. PubMed ID: 20414345
[TBL] [Abstract][Full Text] [Related]
2. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Litzow MR; Winters JL; Markovic SN
Biol Blood Marrow Transplant; 2008 Jul; 14(7):807-16. PubMed ID: 18541201
[TBL] [Abstract][Full Text] [Related]
3. Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Villasboas JC; Markovic SN
Leuk Res; 2019 Jun; 81():1-9. PubMed ID: 30978434
[TBL] [Abstract][Full Text] [Related]
4. Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Hogan WJ; Markovic SN
J Hematol Oncol; 2015 Jul; 8():80. PubMed ID: 26138828
[TBL] [Abstract][Full Text] [Related]
5. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma.
Porrata LF; Litzow MR; Inwards DJ; Gastineau DA; Moore SB; Pineda AA; Bundy KL; Padley DJ; Persky D; Ansell SM; Micallef IN; Markovic SN
Bone Marrow Transplant; 2004 Feb; 33(3):291-8. PubMed ID: 14676784
[TBL] [Abstract][Full Text] [Related]
6. Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma.
Porrata LF; Burgstaler EA; Winters JL; Jacob EK; Gastineau DA; Suman VJ; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nevala W; Markovic SN
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1017-1023. PubMed ID: 26826432
[TBL] [Abstract][Full Text] [Related]
7. Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.
Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Trachtenberg E; Haagenson MD; Spellman SR; Ladner M; Guethlein LA; Parham P; Miller JS; Cooley SA
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1602-1607. PubMed ID: 27220262
[TBL] [Abstract][Full Text] [Related]
8. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Majolino I; Pearce R; Taghipour G; Goldstone AH
J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
[TBL] [Abstract][Full Text] [Related]
9. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphocyte collection target.
Katipamula R; Porrata LF; Gastineau DA; Markovic SN; Moore SB; Greiner C; Burgstaler EA; Padley DJ; Winters JL
Bone Marrow Transplant; 2006 May; 37(9):811-7. PubMed ID: 16532018
[TBL] [Abstract][Full Text] [Related]
10. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.
Bachanova V; Sarhan D; DeFor TE; Cooley S; Panoskaltsis-Mortari A; Blazar BR; Curtsinger JM; Burns L; Weisdorf DJ; Miller JS
Cancer Immunol Immunother; 2018 Mar; 67(3):483-494. PubMed ID: 29218366
[TBL] [Abstract][Full Text] [Related]
11. Day 100 Natural Killer Cell/CD14+HLA-DR
Porrata LF; Ansell SM; Micallef IN; Johnston PB; Villasboas JC; Paludo J; Durani U; Markovic SN
Clin Transplant; 2024 Jan; 38(1):e15211. PubMed ID: 38041479
[TBL] [Abstract][Full Text] [Related]
12. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
Porrata LF; Gertz MA; Inwards DJ; Litzow MR; Lacy MQ; Tefferi A; Gastineau DA; Dispenzieri A; Ansell SM; Micallef IN; Geyer SM; Markovic SN
Blood; 2001 Aug; 98(3):579-85. PubMed ID: 11468153
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
14. NK Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation: Association Between NK Cell Maturation Stage and Outcome in Multiple Myeloma.
Orrantia A; Terrén I; Astarloa-Pando G; González C; Uranga A; Mateos-Mazón JJ; García-Ruiz JC; Riñón M; Rey M; Pérez-Fernandez S; Zenarruzabeitia O; Borrego F
Front Immunol; 2021; 12():748207. PubMed ID: 34675932
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
17. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
19. Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance.
Valtola J; Varmavuo V; Ropponen A; Selander T; Kuittinen O; Kuitunen H; Keskinen L; Vasala K; Nousiainen T; Mäntymaa P; Pelkonen J; Jantunen E
Leuk Lymphoma; 2016 Sep; 57(9):2025-32. PubMed ID: 26763346
[TBL] [Abstract][Full Text] [Related]
20. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
